series-a
Stage
1
Investors
About
Serpin Pharma develops targeted peptide therapeutics that modulate the immune response by binding to the LRP1 receptor to reduce inflammation and restore immune balance, with a lead compound SP16 focused on treating acute myocardial infarction and other inflammatory conditions.
Explore Serpin Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.